Sprint Bioscience AB publ announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was SEK 12,000 compared to SEK 5.807 million a year ago. Operating loss was SEK 14.728 million compared to SEK 10.071 million a year ago. Net loss was SEK 13.915 million compared to SEK 12.510 million a year ago. Basic loss per share from continuing operations was SEK 0.6 compared to SEK 1.01 a year ago. For the half year, total revenue was SEK 419,000 compared to SEK 11.323 million a year ago. Operating loss was SEK 27.762 million compared to SEK 19.567 million a year ago. Net loss was SEK 27.610 million compared to SEK 22.283 million a year ago. Basic loss per share from continuing operations was SEK 1.19 compared to SEK 1.81 a year ago.